Sage Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
42.59 |
84.57 |
120.72 |
164.24 |
200.59 |
235.46 |
| Przychód Δ r/r |
0.00% |
98.54% |
42.75% |
36.06% |
22.13% |
17.39% |
| Przychód (min) |
40.54 |
60.31 |
79.41 |
164.24 |
152.83 |
179.41 |
| Przychód (max) |
45.45 |
123.38 |
175.31 |
164.25 |
266.98 |
313.41 |
| EBITDA (średnia) |
-29.28 |
-58.14 |
-83.00 |
-112.92 |
-137.91 |
-161.89 |
| EBIT (średnia) |
-29.30 |
-58.18 |
-83.05 |
-113.00 |
-138.00 |
-162.00 |
| EBIT % |
-68.80% |
-68.80% |
-68.80% |
-68.80% |
-68.80% |
-68.80% |
| Zysk netto (średni) |
-394.12 |
-216.67 |
-194.27 |
-151.02 |
-65.48 |
-31.98 |
| Zysk netto % |
-925.28% |
-256.21% |
-160.93% |
-91.95% |
-32.64% |
-13.58% |
| EPS (średnia) |
-6.46 |
-3.57 |
-2.70 |
-1.70 |
-1.08 |
-0.53 |
| Liczba analityków (Przychody) |
15 |
5 |
11 |
11 |
4 |
5 |
| Liczba analityków (EPS) |
12 |
6 |
8 |
10 |
5 |
4 |
| symbol |
SAGE |
SAGE |
SAGE |
SAGE |
SAGE |
SAGE |